ReviewCirculation2021
Lower Extremity Peripheral Artery Disease: Contemporary Epidemiology, Management Gaps, and Future Directions: A Scientific Statement From the American Heart Association.
Review in Circulation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 356 papers, 10 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Innova Breeze®-Based Roadmap for Peripheral Arterial Disease
MRI Guided Management of Occlusive Peripheral Arterial Disease
Who cites it
356 citing papers in PubMed, 10 syntheses or guidelines pooled it, 720 citations in OpenAlex.
- 2026 ACC/AHA Clinical Performance and Quality Measures for Patients With Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Performance Measures.Journal of the American College of Cardiology · 2026Guideline
- Percutaneous Transluminal Angioplasty for Infrapopliteal Chronic Limb-Threatening Ischemia: A Systematic Review and Meta-analysis of Primary Patency and Binary Restenosis Rates.Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists · 2025Pooled it
- Systematic review of the use of oral anticoagulants in patients with peripheral arterial disease.Future cardiology · 2025Pooled it
- Burden of peripheral artery disease and risk factors among patients with diabetes mellitus in sub-Saharan Africa: a systematic review and meta-analysis.BMC endocrine disorders · 2025Pooled it
- Exploring the prevalence and risk factors of peripheral artery disease in patients with type 2 diabetes in sub-Saharan Africa: a systematic review and meta-analysis.Frontiers in clinical diabetes and healthcare · 2025Pooled it
- Quality of life and utility of patients with peripheral artery disease (PAD): a systematic review and meta-analysis.Scientific reports · 2024Pooled it
- Reported outcomes in studies of intermittent claudication - first step toward a core outcome set: systematic review.BJS open · 2024Pooled it
- Peripheral artery disease: an underdiagnosed condition in familial hypercholesterolemia? A systematic review.Endocrine · 2024Pooled it
- 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.Journal of the American College of Cardiology · 2024Guideline
- Guideline
- Effect of Buerger-Allen Exercises on Lower Extremity Perfusion in Diabetes Mellitus Patients Undergoing Coronary Artery Bypass Grafting With Saphenous Vein Harvesting: A Randomized Controlled Trial.Physiotherapy research international : the journal for researchers and clinicians in physical therapy · 2026Trial
- Rivaroxaban in Peripheral Artery Disease After Revascularization: Worst Events and Net Outcomes in VOYAGER PAD.Journal of the American Heart Association · 2025Trial
- Trial
- Effects of NADThe Journal of pharmacology and experimental therapeutics · 2025Trial
- Effect of enhanced external counterpulsation versus individual shear rate therapy on the peripheral artery functions.Scientific reports · 2024Trial
- Trial
- Polymer-based drug-eluting stent treatment extends the time to reintervention for patients with symptomatic femoropopliteal artery disease: clinical evidence and potential economic value.Journal of comparative effectiveness research · 2024Trial
- Non-Vigorous Physical Activity Associated with Reduced Hospitalization Risk with or without Diabetes or Peripheral Artery Disease: Study of Latinos.Medicine and science in sports and exercise · 2026Article
- Accelerated biological aging, genetic susceptibility, and the risk of peripheral arterial disease: Evidence from the UK Biobank cohort study.International journal of cardiology. Cardiovascular risk and prevention · 2026Article
- Association of the C-reactive protein-triglyceride-glucose index (CTI) with lower-extremity peripheral artery disease among U.S. adults.Atherosclerosis plus · 2026Article
296 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
Abstract
Lower extremity peripheral artery disease (PAD) affects >230 million adults worldwide and is associated with increased risk of various adverse clinical outcomes (other cardiovascular diseases such as coronary heart disease and stroke and leg outcomes such as amputation). Despite its prevalence and clinical importance, PAD has been historically underappreciated by health care professionals and patients. This underappreciation seems multifactorial (eg, limited availability of the first-line diagnostic test, the ankle-brachial index, in clinics; incorrect perceptions that a leg vascular disease is not fatal and that the diagnosis of PAD would not necessarily change clinical practice). In the past several years, a body of evidence has indicated that these perceptions are incorrect. Several studies have consistently demonstrated that many patients with PAD are not receiving evidence-based therapies. Thus, this scientific statement provides an update for health care professionals regarding contemporary epidemiology (eg, prevalence, temporal trends, risk factors, and complications) of PAD, the present status of diagnosis (physiological tests and imaging modalities), and the major gaps in the management of PAD (eg, medications, exercise therapy, and revascularization). The statement also lists key gaps in research, clinical practice, and implementation related to PAD. Orchestrated efforts among different parties (eg, health care providers, researchers, expert organizations, and health care organizations) will be needed to increase the awareness and understanding of PAD and improve the diagnostic approaches, management, and prognosis of PAD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.